Hubungan antara Platelet Lymphocyte Ratio (PLR) dan respon Neoadjuvant Chemotherapy (NAC) CAF pada pasien Locally Advanced Breast Cancer

Background: The incidence of LABC (Locally Advanced Breast Cancer) in Indonesia is estimated more than 50%, and in Bali as many as 76.3% from all of breast cancer cases. Response of NAC (Neoadjuvant chemotherapy) in LABC case is not the same on each patient. Currently, there are several biomarkers that can be a predictor of NAC response on LABC. One of them is PLR (platelet lymphocyte ratio). PLR is an easy, cheap and fast marker to be counted, but not all clinicians know its role. Lack of research in the relationship of PLR to NAC CAF (Cyclophospamide, Adriamycin, 5 Flourouracil) response in patients with LABC are currently making researchers interested in studying it. Method: This research is observational analytics, using a retrospective cohort study. The number of samples was 62 (consecutive sampling), obtained from the medical records of patients who had undergone NAC CAF from 2015-2019 at Sanglah Hospital Denpasar. PLR value and initial tumor size were calculated before undergoing chemotherapy, then assessed the NAC CAF response to tumors after undergoing 3 cycles of chemotherapy. Positive response if tumor size is reduced and negative response if the tumor size is persists or enlarges. In this study use a cut off point of PLR 150. Results: From 62 respondents obtained PLR value ? 150 had a positive response of 77.1% and 22.9% had a negative response. From these results obtained a correlation between PLR value with responses to NAC CAF in LABC patients, where low PLR values had positive responses 1.6 times (IK 95; 1.04 - 2.47) with an output value of p = 0.018. Conclusion: There is a correlation between PLR and NAC CAF response, where a low PLR value (PLR ? 150) has a positive response to NAC CAF in LABC patients. Keyword: PLR (Platelet lymphocyte ratio), NAC (Neoadjuvant chemotherapy), CAF (Cyclophospamide, Adriamycin, 5 Flourouracil), LABC (Locally Advanced Breast Cancer).